Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race

With last week's FDA approval of Attruby (acoramidis), BridgeBio may reach transthyretin amyloid cardiomyopathy (ATTR-CM) patients first, but Alnylam isn't far behind. The company used a priority review voucher as part of its regulatory submission for RNAi therapeutic vutrisiran, which the US regulator accepted on Monday and granted a PDUFA date of March 23, 2025.